KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.Am J Perinatol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:研究设计图。PMID 41290206PMC133456972026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.Allergy入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41358486PMC133427812026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.J Eur Acad Dermatol Venereol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41405008PMC133086612026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41571044无 PMCID2026-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.J Thorac Oncol已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 flow diagram;Figure 3A:AI 判定为 other;Figure 3B:AI 判定为 other;Figure 4A:AI 判定为 other;另有 1 张未列出。PMID 41747891PMC130951402026-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.Lancet HIVPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41763226无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema.Contact Dermatitis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:AI 判定为 other。PMID 41775339PMC132384502026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41786248无 PMCID2026-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks.Clin Exp AllergyPMID 41786301PMC133271672026-Jul0.98未发现恶性肿瘤人群证据。已完成
Win Ratio Analysis to Clarify Clinical Benefits: A Post Hoc Analysis of Phase 3 BOREAS and NOTUS (Two Pivotal Studies to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-Severe COPD With Type 2 Inflammation).ChestPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41794122无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial.Eur J Nucl Med Mol Imaging已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:AI 判定为 other。PMID 41801367PMC132497842026-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension.Chest入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41802593无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41833903无 PMCID2026-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.J Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41834413无 PMCID2026-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.Eur J Haematol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41857682无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.J Pediatr Gastroenterol Nutr入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41858082PMC133427602026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.Am J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41865857无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study.Eur Neuropsychopharmacol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41880832无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome.EpilepsiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41891667无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial.ChestPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41895581无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.EpilepsiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41902639无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders.J Pediatr Gastroenterol Nutr入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41913506PMC133427842026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up.EsophagusPMID 41917381PMC133196362026-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate-use seizure medication.EpilepsiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41919765无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.Aliment Pharmacol Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 multi panel km;FIGURE 2:AI 判定为 other;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图;另有 1 张未列出。PMID 41933275PMC132515882026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41937031无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.Am J HematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41943179无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.Ophthalmic Physiol OptPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41949794无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Impact of vitamin D status and supplementation on exploratory inflammatory biomarkers in preschoolers with asthma.Ann Allergy Asthma ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41966354无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Structural and construct validity assessment of the schizophrenia cognition rating scale (SCoRS) using data from three international phase 3 randomized controlled trials (CONNEX programme).Schizophr ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41967302无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT).Ann Allergy Asthma ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41967704无 PMCID2026-Jul0.97方案论文未报告临床试验结果。无 KM 图
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.Br J CancerPMID 41975042PMC132701492026-Jul0.85The record describes a pharmacokinetic-based exposure-response analysis for efficacy and safety, which is a secondary analysis. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as required. Therefore, it is ineligible.已完成
Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.HIV Med已检查 1 张 PMC Figure,均未识别为 KM 图:FIGURE 1:ROC 图。PMID 41992416PMC133409342026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41999978无 PMCID2026-Jul0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42025759无 PMCID2026-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.Diabetes Obes MetabPMID 42027097PMC132439512026-Jul0.98未发现恶性肿瘤人群证据。处理中
Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials.Clin Exp Allergy已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE A1:生活质量量表图。PMID 42036875PMC133271392026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:森林图/亚组分析图;FIGURE 3:AI 判定为 other。PMID 42046405PMC132439682026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.EsophagusPMID 42047965PMC133198942026-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.Kidney IntPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42055319无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL).Palliat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:生活质量量表图。PMID 42059487PMC133239282026-Jul0.90The study meets criteria for oncology, human, randomized, Phase III, and original trial with drug intervention. However, it is ineligible because the reported efficacy endpoints are quality-of-life, weight, cost, and biomarker outcomes. No primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) is reported.无 KM 图
Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42067068无 PMCID2026-Jul0.95The study is a randomized Phase III trial in oncology (breast cancer) but evaluates a non-drug intervention (radiotherapy schedules) and reports a binary incidence outcome (5-year arm swelling) analyzed with logistic regression. It does not have a drug-containing arm or a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) suitable for Kaplan-Meier digitization.无 KM 图
Lifitegrast ophthalmic solution 5.0% (KH732) for dry eye disease: A randomized, multicenter, double-masked, vehicle-controlled phase 3 trial.Ocul SurfPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42069335无 PMCID2026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:森林图/亚组分析图;FIGURE 3:森林图/亚组分析图。PMID 42070786PMC132439802026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study.Diabetes Obes Metab已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:ROC 图。PMID 42070788PMC132439982026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.Gastric CancerPMID 42095986PMC133146792026-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.Int J Clin Oncol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram。PMID 42098463PMC133035652026-Jul0.85The study is a randomized, phase III oncology trial with a drug intervention and original results. However, it does not include a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is pharmacokinetic (serum trough concentration), and secondary endpoints include pathological complete response and safety.无 KM 图
Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial.J Clin OncolPMID 42114027PMC131660902026-Jul0.95Study is a Phase III randomized trial with time-to-event endpoints (IBR, DFS, OS) and reports primary results, but the intervention compares radiation therapy regimens and does not include a drug-containing intervention.已完成
Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.BioDrugs已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。PMID 42120652PMC133379502026-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42127535无 PMCID2026-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图